Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Whitehawk Therapeutics (WHWK) Income from Continuing Operations (2018 - 2025)

Whitehawk Therapeutics (WHWK) has disclosed Income from Continuing Operations for 8 consecutive years, with 17696000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Income from Continuing Operations fell 41.06% to 17696000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was 103166000.0, a 67.25% decrease, with the full-year FY2024 number at 63691000.0, up 3.15% from a year prior.
  • Income from Continuing Operations was 17696000.0 for Q3 2025 at Whitehawk Therapeutics, up from 52770000.0 in the prior quarter.
  • In the past five years, Income from Continuing Operations ranged from a high of 1536000.0 in Q2 2021 to a low of 87088000.0 in Q3 2021.
  • A 5-year average of 20260421.05 and a median of 15990000.0 in 2021 define the central range for Income from Continuing Operations.
  • Peak YoY movement for Income from Continuing Operations: crashed 1386.04% in 2021, then surged 83.38% in 2022.
  • Whitehawk Therapeutics' Income from Continuing Operations stood at 15990000.0 in 2021, then grew by 12.99% to 13913000.0 in 2022, then fell by 16.93% to 16269000.0 in 2023, then decreased by 12.32% to 18273000.0 in 2024, then rose by 3.16% to 17696000.0 in 2025.
  • Per Business Quant, the three most recent readings for WHWK's Income from Continuing Operations are 17696000.0 (Q3 2025), 52770000.0 (Q2 2025), and 14427000.0 (Q1 2025).